Q2 2026 Sophia Genetics SA Earnings Call Transcript
Key Points
- Revenue grew 27% year-over-year in Q2, with U.S. revenue up 64% and liquid biopsy revenue up 80%.
- Record 115,000 patient analyses in Q2, with 24 new customers and net dollar retention of 117%.
- Announced two companion diagnostic programs with AstraZeneca, a significant milestone for future revenue.
- Signed an MOU with Memorial Sloan Kettering to form a joint venture for AI-driven precision oncology.
- Raised full-year revenue guidance to $94-$96 million (22-24% growth) and improved adjusted EBITDA loss by 27% year-over-year.
- Closed an oversubscribed public offering, raising $57.5 million, bringing cash to $107.7 million to fund growth.
- Adjusted gross margin declined to 72.1% from 74.4% in Q2 2025, due to lower-margin biopharma and services revenue.
- Operating expenses increased to $35.1 million, impacted by $1.25 million in restructuring costs and $1.1 million in litigation expenses.
- Cash burn increased to $12.9 million in Q2, up from $11.9 million, due to restructuring and legal costs.
- The company still expects to approach adjusted EBITDA breakeven only by end of 2026, with positive EBITDA not until second-half 2027.
- Gross margin pressure is expected to continue in the near term due to new customer implementations and pharma project launches.
- The CDX deals with AstraZeneca will have minimal revenue contribution in 2026, with most impact deferred to 2027 and beyond.
Good morning. My name is Joelle, and I will be your conference operator today. At this time, I would like to welcome everyone to the Sophia Genetics Second Quarter 2026 Earnings Conference Call.
Following the presentation, we will conduct a question-and-answer session. If at any time during this call you require immediate assistance, please press stars here for the operator. This call is being recorded on Tuesday, August 4th, 2026. I would now like to turn the conference over to Callan Sandra, Sophia Genetics Head of Strategy. You may begin.
Thank you, and good morning, everyone. Welcome to the Sophia Genetics Second Quarter 2026 Earnings Conference Call. Joining me today to discuss the results are Ross Muchin, our Chief Executive Officer, and George Cardosa, our Chief Financial Officer. I'd like to remind you that management will make statements during this call that are forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
